We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Long-Acting Injectable to Prevent HIV Not Cost-Effective, Study Finds
Long-Acting Injectable to Prevent HIV Not Cost-Effective, Study Finds
ViiV Healthcare’s Apretude (cabotegravir), a recently approved long-acting injectable for preventing HIV in adults and adolescents, isn’t cost-effective despite offering new hope against the deadly disease, a new analysis contends.